Product Liability in U.S. Accident Law

Product liability is the body of U.S. tort law governing civil claims against manufacturers, distributors, and sellers when a defective product causes personal injury or property damage. This page covers the doctrinal foundations, the three recognized defect categories, the causal frameworks courts apply, classification boundaries between claim types, and the procedural sequence from defect identification through resolution. The subject carries broad practical consequence because defective products generate both individual injury claims and large-scale mass tort litigation across every consumer and industrial sector.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix
• References

Definition and Scope

Product liability law imposes civil responsibility on parties in a product's commercial chain when that product causes harm through a defect in design, manufacture, or the adequacy of its warnings. The doctrine sits within the broader framework of tort law foundations governing accident claims but diverges from ordinary negligence by permitting strict liability — meaning a plaintiff need not prove the defendant acted carelessly, only that the product was defective and that defect caused the harm.

The Restatement (Third) of Torts: Products Liability (1998), published by the American Law Institute (ALI), is the primary secondary authority organizing U.S. product liability doctrine. It superseded the influential strict liability rule of Restatement (Second) § 402A (1965), which first established that sellers of unreasonably dangerous products bear liability regardless of negligence. The shift to the Third Restatement introduced defect-category-specific standards rather than a single universal test.

Who can be held liable extends well beyond the original manufacturer. Under most state frameworks, liability can attach to component-part manufacturers, assembly plants, wholesale distributors, retail sellers, and importers who place foreign-manufactured goods into the U.S. stream of commerce. The Federal Consumer Product Safety Commission (CPSC) (www.cpsc.gov) administers recall authority under the Consumer Product Safety Act (15 U.S.C. §§ 2051–2089), which runs parallel to private tort claims — a CPSC recall does not preempt civil liability, nor does the absence of a recall establish that a product was safe.

Scope boundaries matter: purely economic loss without accompanying personal injury or property damage is generally excluded from tort recovery under the economic loss rule, leaving those claims to contract or warranty law. Claims involving pharmaceutical drugs and medical devices occupy a partially preempted zone governed by the Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) and enforced by the U.S. Food and Drug Administration (FDA) (www.fda.gov).

Core Mechanics or Structure

Product liability claims are structured around three analytically distinct defect categories, each with its own standard of proof and evidentiary demands.

Manufacturing Defect

A manufacturing defect occurs when a specific unit deviates from the product's own intended design during production. Courts apply a departure-from-specification test: the product as produced differs from the product as designed in a way that renders it unreasonably dangerous. Strict liability applies under this category in the large majority of U.S. jurisdictions — the plaintiff proves the deviation and the resulting harm, without establishing that the manufacturer failed to exercise reasonable care. The design-defect and manufacturing-defect framework treats these as legally separate even when they arise from the same incident.

Design Defect

A design defect means the entire product line is defective because of choices made at the design stage, not a production error on a single unit. Two competing tests define whether a design is legally defective:

• Consumer Expectations Test: The product failed to perform as safely as an ordinary consumer would expect. This standard, rooted in Restatement (Second) § 402A, remains operative in states including California (Barker v. Lull Engineering Co., 20 Cal.3d 413 (1978)).
• Risk-Utility Test: The foreseeable risks of harm from the design outweigh the design's benefits. The Restatement (Third) of Torts: Products Liability § 2(b) (ALI 1998) adopts risk-utility as the primary test and requires plaintiffs to identify a reasonable alternative design (RAD) that would have reduced or eliminated the risk.

Whether a RAD must be proven is one of the most contested doctrinal questions in U.S. product liability, with states divided on the requirement.

Warning Defect (Failure to Warn)

A warning defect arises when a product carries an inherent risk that is not obvious to an ordinary user and the manufacturer failed to provide adequate instructions or warnings. The standard is whether a reasonable manufacturer in the same position would have provided different or additional warnings. The learned intermediary doctrine — recognized by the FDA in the context of prescription drugs (21 C.F.R. § 201.57) — shifts warning obligations to prescribing physicians rather than directly to patients in most pharmaceutical cases.

Causal Relationships or Drivers

Establishing liability requires proving two distinct causal links: actual cause (but-for or substantial factor causation) and proximate cause (foreseeability of the type of harm). This mirrors the general accident claim burden of proof structure but carries product-specific complications.

Defect-causation chain: The plaintiff must show the defect existed when the product left the defendant's control and that the defect — not user misuse or an independent intervening cause — produced the injury. Chain-of-custody evidence becomes critical in manufacturing defect cases, where the specific unit must often be physically examined and tested.

Sophisticated intermediary problem: In industrial and chemical product cases, manufacturers sometimes argue that a sophisticated business purchaser (not an end consumer) bore responsibility for conveying warnings downstream. The Restatement (Third) § 2, comment i, addresses this allocation directly.

Regulatory compliance as causation factor: Compliance with CPSC safety standards or FDA premarket approval does not automatically defeat a product liability claim under most state laws (with some statutory exceptions for certain FDA-approved devices under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), which held that FDA premarket approval expressly preempts conflicting state tort requirements for Class III medical devices).

Post-sale duty to warn: Courts in states including New Jersey and California have recognized a post-sale duty to warn when a manufacturer learns of a danger after the product is distributed. This extends the liability window beyond the original sale transaction.

Classification Boundaries

Product liability intersects with and must be distinguished from adjacent legal categories:

Product liability vs. negligence: Ordinary negligence doctrine requires proving the defendant breached a standard of reasonable care. Strict product liability removes that requirement for manufacturing defects and, in some jurisdictions, for design defects — fault is irrelevant if the product is proven defective. Negligence and strict liability theories are frequently pleaded simultaneously in the same complaint.

Product liability vs. warranty claims: Breach of implied warranty of merchantability (Uniform Commercial Code § 2-314) and product liability in tort overlap significantly but differ in privity requirements, economic loss rules, and notice obligations. Most courts permit both to proceed independently.

Product liability vs. premises liability: When a defective product injures someone on another party's property, the injured party may have claims under both premises liability doctrine and product liability, against different defendants.

Product liability vs. workers' compensation: When a defective product injures an employee at work, workers' compensation is the exclusive remedy against the employer, but the employee retains a full third-party product liability claim against the manufacturer.

Class actions vs. mass torts: Widespread product injuries may be litigated as class actions or as individual cases aggregated through multidistrict litigation (MDL), depending on the degree of case commonality. Most large-scale pharmaceutical and medical device cases proceed through MDL rather than class certification.

Tradeoffs and Tensions

Strict liability vs. negligence standard for design defects: Jurisdictions that apply the consumer expectations test without requiring a reasonable alternative design lower the barrier for plaintiffs but risk creating liability for products that could not have been made meaningfully safer. Jurisdictions requiring a RAD protect innovation incentives but may leave genuinely dangerous products on the market when alternative designs are difficult to specify before litigation.

Preemption vs. state tort remedies: Federal preemption doctrine — most aggressively applied to Class III medical devices after Riegel v. Medtronic (2008) and to generic drug labeling after PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) — eliminates state tort claims in preempted fields, leaving injured plaintiffs without a damages remedy even when federal regulatory compliance was minimal. This tension between regulatory uniformity and victim compensation remains active in FDA-regulated product litigation.

Punitive damages availability: Punitive damages are available in product liability cases when a defendant knowingly sold a dangerous product despite awareness of the risk. But damage caps in 32 states as of ALI's published surveys limit punitive awards, creating geographic disparities in deterrence and recovery.

Repose statutes: Most states impose a statute of repose for product claims — typically 10 to 15 years from the date of product sale — that can bar claims even before a plaintiff discovers an injury. This is distinct from the statute of limitations, which runs from discovery of harm.

Common Misconceptions

Misconception: A product must have caused a defect to be recalled for a claim to exist.
Correction: A CPSC recall and a viable tort claim are legally independent. Products can generate successful tort claims without any recall, and recalled products do not automatically produce successful litigation — proof of a specific defect causing specific harm is still required.

Misconception: Only the original manufacturer faces product liability.
Correction: Retailers, importers, and distributors are routinely named as defendants. Under the stream-of-commerce theory adopted in states including New Jersey, any commercial seller who profits from placing a product in distribution bears potential strict liability.

Misconception: Assumption of risk defeats a product claim if the plaintiff knew the product was dangerous.
Correction: Comparative fault principles have largely displaced pure assumption of risk as a complete bar in product liability. In states following comparative fault rules, a plaintiff's awareness of a risk reduces recovery proportionally under comparative negligence doctrine rather than eliminating it entirely.

Misconception: Warning labels eliminate liability.
Correction: Adequate warnings can defeat a failure-to-warn claim, but they cannot cure a design defect or a manufacturing defect. A product that is unreasonably dangerous by design remains actionable even with extensive labeling.

Misconception: Product liability requires physical injury.
Correction: Property damage without personal injury is recoverable in product liability if it is caused by a defective product and does not fall within the economic loss rule. The specific rules vary by state and are covered in the personal injury vs. property damage claims framework.

Checklist or Steps (Non-Advisory)

The following sequence describes the analytical and procedural stages of a U.S. product liability claim. This is a reference framework, not procedural instruction.

Stage 1 — Defect Identification
- Identify which defect category applies: manufacturing deviation, design inadequacy, or warning failure
- Preserve the physical product and all packaging; chain of custody begins at discovery of the defect
- Document the injury and the conditions of product use at the time of injury
- Determine the specific unit, lot number, or batch involved

Stage 2 — Supply-Chain Mapping
- Identify the full commercial chain: component manufacturers, assemblers, distributors, importers, and retailers
- Obtain product specifications, design documents, and applicable CPSC or FDA regulatory history
- Research whether CPSC has issued any safety bulletins or prior recall notices for the product line

Stage 3 — Regulatory Research
- Determine whether the product is governed by CPSC jurisdiction, FDA jurisdiction (drugs, devices, biologics), National Highway Traffic Safety Administration (NHTSA) vehicle safety standards (49 C.F.R. Part 571), or another federal safety framework
- Assess federal preemption exposure — particularly for FDA premarket-approved Class III medical devices under Riegel

Stage 4 — Expert Development
- Identify qualified engineering, medical, or scientific experts to establish defect existence, causation, and damages
- Expert witnesses in accident cases in product liability matters typically include failure analysis engineers, human factors specialists, and treating or forensic medical professionals

Stage 5 — Filing and Jurisdiction
- Determine proper jurisdiction and venue, noting that product cases often involve out-of-state corporate defendants and may qualify for federal diversity jurisdiction under 28 U.S.C. § 1332
- File within the applicable statute of limitations and any applicable statute of repose for the relevant state

Stage 6 — Discovery
- Pursue internal corporate communications, design history files, pre-market testing records, and post-market complaint databases through the discovery process
- Address spoliation risk for electronically stored evidence

Stage 7 — Resolution
- Evaluate settlement parameters including economic and noneconomic damages under applicable state caps
- If trial proceeds, assess whether the case presents class or MDL characteristics relevant to consolidation

Reference Table or Matrix

References

• American Law Institute — Restatement (Third) of Torts: Products Liability (1998)
• American Law Institute — Restatement (Second) of Torts § 402A (1965)
• [U.S. Consumer Product Safety Commission (CPSC) — Consumer Product Safety Act, 15 U.S.C. §§ 2051–2089](